Drug General Information
Drug ID
D0V4RH
Former ID
DCL000308
Drug Name
Lobucavir
Synonyms
Cygalovir; Carbocyclic oxetanocin G; Bms 180194; SQ 33054; A-69992; BMS-180194; Cyclobut-G; DRG-0235; Lobucavir [USAN:INN]; SQ 34,514; SQ-34514; C-Oxetanocin-G; C-Oxt-G; Lobucavir (USAN/INN); SQ-33,054; [1R-1.alpha.,2.beta.,3.alpha.]-2-Amino-9-[2,3-bis(hydroxymethyl)cyclobutyl]-6H-purin-6-one; (+)-Cyclobut G; (+)-Cyclobut-G; (+-)-Cyclobut-G; (+/-)-9-[2,3-Bis(hydroxymethyl)-1-cyclobutyl]guanine; (+/-)-BHCG; (+/-)-Cyclobut-G; (+/-)-Lobucavir; (R)-9-[2,3-Bis(hydroxymethyl)-1-cyclobutyl]guanine; (R)-BHCG;2-Amino-9-(2,3-bis(hydroxymethyl)cyclobutyl)-1,9-dihydro-6H-purin-6-one; 2-amino-9-[(1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl]-3H-purin-6-one; 2-amino-9-[(1r,2r,3s)-2,3-bis(hydroxymethyl)cyclobutyl]-1,9-dihydro-6h-purin-6-one; 6H-Purin-6-one, 2-amino-9-(2,3-bis(hydroxymethyl)cyclobutyl)-1,9-dihydro, (1R-(1alpha,2beta,3alpha)); 9-((1R,2R,3S)-2,3-Bis(hydroxymethyl)cyclobutyl)guanine; 9-(2,3-Bis-(hydroxymethyl)-1-cyclobutyl)guanine; 9-[1.beta.-2.alpha.-3.beta.]-2,3-Bis(hydroxymethyl)-1-cyclobutyl]guanine
Drug Type
Small molecular drug
Indication Viral infections [ICD9: 054.0, 054.1, 054.2, 054.3, 075, 771.2, 052, 053; ICD10:B01, B02, A60, B00, B27, G05.1, P35.2] Discontinued in Phase 3 [545123]
Company
Bristol-Myers Squibb
Structure
Download
2D MOL

3D MOL

Formula
C11H15N5O3
Canonical SMILES
C1C(C(C1N2C=NC3=C2NC(=NC3=O)N)CO)CO
InChI
1S/C11H15N5O3/c12-11-14-9-8(10(19)15-11)13-4-16(9)7-1-5(2-17)6(7)3-18/h4-7,17-18H,1-3H2,(H3,12,14,15,19)/t5-,6-,7-/m1/s1
InChIKey
GWFOVSGRNGAGDL-FSDSQADBSA-N
CAS Number
CAS 127759-89-1
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) HIV reverse transcriptase Target Info Modulator
References
Ref 545123Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002213)

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.